1-10 of 10
Rebecca Bishop
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Clinical Trials & Observations
Sridhar Chaganti, Shanna Maycock, Graham McIlroy, Aimee Jackson, Rebecca Bishop, Sarah Johnson, Edward Kanfer, Shireen Kassam, Kate Cwynarski, David Wrench, Arvind Arumainathan, Christopher P. Fox, Rod Johnson, Pam McKay, Shankara Paneesha, Clare Rowntree, Constantine Balotis, Graham P. Collins, Andrew Davies, Josh Wright, Sarah Burns, Arian Laurence, Keith Wheatley, Tobias Menne
Journal: Blood
Blood (2024) 144 (4): 392–401.
https://doi.org/10.1182/blood.2024023847
Published: 2024
Includes: Supplemental data
Journal Articles

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Charles Craddock, David Marks, Victoria Potter, Wendy A Ingram, Rebecca Collings, Eleni Tholouli, Rachel Protheroe, Hugh Allen, Alex Ross, Dawn Farrar, Shamyla Siddique, Rebecca Bishop, Ronjon Chakraverty
Journal: Blood
Blood (2023) 142 (Supplement 1): 5097.
https://doi.org/10.1182/blood-2023-188490
Published: 2023
Journal Articles

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation

Giovanna Lucchini, Elena Cozma, Aimee Jackson, Kimberly Gilmour, Rachel Elizabeth Protheroe, Eleni Tholouli, Robert F Wynn, Keith Wilson, Karl S Peggs, Victoria Potter, Anne Parker, Charles Craddock, Shankara Paneesha, Emma Nicholson, David I. Marks, Oana Mirci-Danicar, Christopher Parrish, Alexander M Martin, Graham McIlroy, Rebecca Bishop, Rebecca Collings, Ellie Williams, Persis J Amrolia
Journal: Blood
Blood (2021) 138 (Supplement 1): 1788.
https://doi.org/10.1182/blood-2021-146515
Published: 2021
Journal Articles

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jennifer Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, Matthew Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap
Journal: Blood
Blood (2021) 138 (Supplement 1): 312.
https://doi.org/10.1182/blood-2021-147972
Published: 2021
Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat
Journal: Blood
Blood (2019) 134 (Supplement_1): 497.
https://doi.org/10.1182/blood-2019-125591
Published: 2019
Journal Articles

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Andy Rawstron, PhD, Talha Munir, Kristian Brock, MSc, BSc, Nichola Webster, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Sophie Cramp, MSc, BSc, Rebecca Bishop, BSc, Surita Dalal, PhD, Ruth M De Tute, BSc,MSc, Oonagh Sheehy, Andrew Pettitt, FRCPath, PhD, Christopher P. Fox, MD PhD, Stephen Devereux, PhD, Christopher Fegan, MD, Donald MacDonald, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 181.
https://doi.org/10.1182/blood-2018-181
Published: 2018
Journal Articles

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Donald Macdonald, Christopher Fegan, MD, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Christopher P. Fox, MD PhD, Francesco Forconi, MD DM, PhD FRCPath, Talha Munir
Journal: Blood
Blood (2018) 132 (Supplement 1): 182.
https://doi.org/10.1182/blood-2018-182
Published: 2018
Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 428.
https://doi.org/10.1182/blood.V130.Suppl_1.428.428
Published: 2017
Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 2049.
https://doi.org/10.1182/blood.V128.22.2049.2049
Published: 2016
Journal Articles

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

Andy C Rawstron, BSc, PhD, Dena Howard, Lucy McParland, Ruth Mary de Tute, PhD FRCPath, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, PhD, Rebecca Bishop, BSc, Francesca J Yates, PhD MSci, Kristian Brock, MSc, BSc, Samuel Muñoz-Vicente, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 3226.
https://doi.org/10.1182/blood.V128.22.3226.3226
Published: 2016